Previous Posts
- This blog has moved
- Avandia Given Positive Reviews Due to $$$$$?
- The FDA and Drug Approval
- J&J Planned Profit from Risky, Unapproved Uses of ...
- What Are the Different Classes of Drug Recalls?
- What Is the Difference Between Class Action and Mu...
- First Lawsuit for Avandia Filed In Santa Clara Cou...
- Our Involvement in the Yaz®/Yasmin® Litigation
- What Is An FDA Black Box Warning?
- What Is a Drug Recall?
Archives
- April 2008
- May 2008
- May 2009
- June 2009
- July 2009
- August 2009
- September 2009
- October 2009
- November 2009
- December 2009
- January 2010
- February 2010
- March 2010
- April 2010
Click Here to View
Our Other Site
Friday, May 29, 2009
New FDA Guidelines Focus on Emphasizing Risks
The FDA has posted new draft regulations on its website. While these guidelines aren’t binding, they will help improve approval process by avoiding problems with omitting or minimizing important risk factors and information.
The FDA will take public comment for 90 days before issuing new guidelines.
Now the guidelines suggest instead of generally stating "certain monitoring" the label should state exactly what type of monitoring is needed along with its frequency. For example, certain monitoring should be replaced with monthly blood tests for liver damage.
The FDA will be reviewing the "net impression" of advertising to determine if the information relays an accurate impression.
For example, smiling people, changing camera angles, and upbeat music may obscure the more serious message of the potential for harm. The FDA could consider these tactics as overall misleading impression.
Last year, a congressional hearing criticized Schering-Plough’s Nasonex, an anti-allergy medication ad campaign. The ad featured a bee that flew around during a description of side effects but simply hovered while benefits were explained.
For more information please see:
http://www.fda.gov/cder/guidance/7427dft.pdf
http://online.wsj.com/article/SB124339082067457033.html
http://www.reuters.com/article/latestCrisis/idUSN26516199
The FDA will take public comment for 90 days before issuing new guidelines.
Now the guidelines suggest instead of generally stating "certain monitoring" the label should state exactly what type of monitoring is needed along with its frequency. For example, certain monitoring should be replaced with monthly blood tests for liver damage.
The FDA will be reviewing the "net impression" of advertising to determine if the information relays an accurate impression.
For example, smiling people, changing camera angles, and upbeat music may obscure the more serious message of the potential for harm. The FDA could consider these tactics as overall misleading impression.
Last year, a congressional hearing criticized Schering-Plough’s Nasonex, an anti-allergy medication ad campaign. The ad featured a bee that flew around during a description of side effects but simply hovered while benefits were explained.
For more information please see:
http://www.fda.gov/cder/guidance/7427dft.pdf
http://online.wsj.com/article/SB124339082067457033.html
http://www.reuters.com/article/latestCrisis/idUSN26516199
Labels: FDA, guidelines, monitor, Nasonex, regulation
posted by
Jessica
at
2:35 PM
